NextCure, Inc. Files 8-K on Rights and Bylaws
Ticker: NXTC · Form: 8-K · Filed: Jul 14, 2025 · CIK: 1661059
| Field | Detail |
|---|---|
| Company | Nextcure, Inc. (NXTC) |
| Form Type | 8-K |
| Filed Date | Jul 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, bylaws, rights
TL;DR
NextCure filed an 8-K on July 14, 2025, covering changes to security holder rights and corporate bylaws.
AI Summary
On July 14, 2025, NextCure, Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, indicating potential corporate governance changes or updates to its financial reporting structure.
Why It Matters
This filing signals potential changes in how NextCure, Inc. operates and how shareholder rights are structured, which could impact investors' stakes and the company's governance.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to bylaws can indicate significant corporate events that may affect stock value and investor confidence.
Key Numbers
- 001-38905 — Commission File Number (SEC File Number for NextCure, Inc.)
- 251120131 — Film Number (SEC Film Number for the filing)
Key Players & Entities
- NextCure, Inc. (company) — Registrant
- July 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 47-5231247 (ein) — IRS Employer Identification No.
- 240-399-4900 (phone_number) — Registrant's telephone number
FAQ
What specific modifications were made to the rights of NextCure, Inc.'s security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary text.
What amendments were made to NextCure, Inc.'s articles of incorporation or bylaws?
The filing states that amendments were made to the articles of incorporation or bylaws, but the exact nature of these amendments is not detailed in the provided text.
What is the significance of filing financial statements and exhibits in this 8-K?
The inclusion of financial statements and exhibits suggests updates or changes related to the company's financial condition or reporting, potentially linked to the other reported items.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 14, 2025.
What is NextCure, Inc.'s principal executive office address?
NextCure, Inc.'s principal executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 14, 2025 regarding NextCure, Inc. (NXTC).